We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, dual-action AR-13324 and triple-action PG324, are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOA, to treat glaucoma in nearly 20 years.
Mar 6, 2014
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
Mar 5, 2014
Aerie Pharmaceuticals to Present at the 26th Annual ROTH Conference
View all »Events & Presentations
Mar 18, 2014 at 5:00 PM ET
Aerie Pharmaceuticals, Inc. Fourth Quarter and Year End 2013 Earnings Call